Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Onartuzumab (MetMAb) In Combination With 5-Fluorouracil, Folinic Acid, And Oxaliplatin (mFOLFOX6) In Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Brief Summary: This randomized, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2-negative adenocarcinoma of the stomach or gastroesophageal junction. Patients will be randomized in a 1:1 ratio to receive either onartuzumab (MetMAb) or placebo in combination with mFOLFOX6. Patients may continue to receive onartuzumab (MetMAb) or placebo until disease progression, unacceptable toxicity, patient or physician decision to discontinue treatment.


Options:
A: Arm Label: S-1 plus cisplatin; Type: EXPERIMENTAL; Interventions: Drug: s-1 plus cisplatin | Arm Label: 5-Fu plus cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fu plus cisplatin | Intervention Type: DRUG; Name: s-1 plus cisplatin; Assigned to Arm(s): S-1 plus cisplatin | Intervention Type: DRUG; Name: 5-Fu plus cisplatin; Assigned to Arm(s): 5-Fu plus cisplatin
B: Arm Label: Arm A: De-escalation therapy; Type: EXPERIMENTAL; Interventions: Drug: S-1 de-escalation | Arm Label: Arm B: Chemotherapy by Investigator's choice; Type: EXPERIMENTAL; Interventions: Drug: Chemotherapy by Investigator's choice | Intervention Type: DRUG; Name: S-1 de-escalation; Assigned to Arm(s): Arm A: De-escalation therapy | Intervention Type: DRUG; Name: Chemotherapy by Investigator's choice; Assigned to Arm(s): Arm B: Chemotherapy by Investigator's choice
C: Arm Label: TE (Taxotere and Eloxatin); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin | Arm Label: TEF (Taxotere, Eloxatin and 5-FU); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + 5-FU | Arm Label: TEX (Taxotere, Eloxatin and Xeloda); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + Capecitabine | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin; Assigned to Arm(s): TE (Taxotere and Eloxatin) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + 5-FU; Assigned to Arm(s): TEF (Taxotere, Eloxatin and 5-FU) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + Capecitabine; Assigned to Arm(s): TEX (Taxotere, Eloxatin and Xeloda)
D: Arm Label: Onartuzumab (MetMAb) with mFOLFOX6; Type: EXPERIMENTAL; Interventions: Drug: Onartuzumab (MetMAb), Drug: Oxaliplatin, Drug: Folinic acid, Drug: Levofolinic acid, Drug: 5-Fluorouracil | Arm Label: Placebo with mFOLFOX6; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Oxaliplatin, Drug: Folinic acid, Drug: Levofolinic acid, Drug: 5-Fluorouracil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo with mFOLFOX6 | Intervention Type: DRUG; Name: Onartuzumab (MetMAb); Assigned to Arm(s): Onartuzumab (MetMAb) with mFOLFOX6 | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): Onartuzumab (MetMAb) with mFOLFOX6, Placebo with mFOLFOX6 | Intervention Type: DRUG; Name: Folinic acid; Assigned to Arm(s): Onartuzumab (MetMAb) with mFOLFOX6, Placebo with mFOLFOX6 | Intervention Type: DRUG; Name: Levofolinic acid; Assigned to Arm(s): Onartuzumab (MetMAb) with mFOLFOX6, Placebo with mFOLFOX6 | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): Onartuzumab (MetMAb) with mFOLFOX6, Placebo with mFOLFOX6

Answer: D